BAI-2 Antibody (6A12): sc-517130

BAI-2 Antibody (6A12) is a mouse monoclonal IgG3 kappa light chain antibody that detects BAI-2 protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-BAI-2 antibody (6A12) is available as the non-conjugated format. BAI-2, a member of the brain-specific angiogenesis inhibitor family, plays a crucial role in regulating angiogenesis, particularly in the brain, where BAI-2 is expressed in neurons of the cerebral cortex. BAI-2′s primary function is to inhibit the formation of new blood vessels, which is vital for maintaining the delicate balance of vascularization in the central nervous system. BAI-2 expression notably increases during brain development, suggesting BAI-2′s importance in neurodevelopmental processes. Additionally, BAI-2 activity has been linked to the suppression of vascular endothelial growth factor (VEGF) in ischemic conditions, where BAI-2 expression decreases significantly after hypoxia. Understanding the mechanisms by which BAI-2 exerts anti-angiogenic effects could pave the way for novel therapeutic strategies in treating conditions characterized by abnormal blood vessel growth, such as certain cancers and neurodegenerative diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

BAI-2 Antibody (6A12) References:

1. Expression of brain-specific angiogenesis inhibitor 2 (BAI2) in normal and ischemic brain: involvement of BAI2 in the ischemia-induced brain angiogenesis.  |  Kee, HJ., et al. 2002. J Cereb Blood Flow Metab. 22: 1054-67. PMID: 12218411
2. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression.  |  Kaur, B., et al. 2003. Am J Pathol. 162: 19-27. PMID: 12507886
3. Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma.  |  Kee, HJ., et al. 2004. FEBS Lett. 569: 307-16. PMID: 15225653
4. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.  |  Arai, Y., et al. 2014. Hepatology. 59: 1427-34. PMID: 24122810
5. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.  |  Li, F., et al. 2020. Cytokine Growth Factor Rev. 52: 56-67. PMID: 31899106
6. Activation of mouse NBCe1-B by Xenopus laevis and mouse IRBITs: Role of the variable Nt appendage of IRBITs.  |  Wang, M., et al. 2020. Biochim Biophys Acta Biomembr. 1862: 183240. PMID: 32119862
7. Identification of Key Osteoporosis Genes Through Comparative Analysis of Men's and Women's Osteoblast Transcriptomes.  |  Chen, D., et al. 2023. Calcif Tissue Int. 113: 618-629. PMID: 37878026
8. Mitochondrial subtype MB-G3 contains potential novel biomarkers and therapeutic targets associated with prognosis of medulloblastoma.  |  Li, Q., et al. 2023. Biomarkers. 28: 643-651. PMID: 37886818
9. Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review.  |  Washburn, L., et al. 2023. J Gastrointest Oncol. 14: 2627-2636. PMID: 38196530
10. Identification of new microtubule small-molecule inhibitors and microtubule-associated genes against triple negative breast cancer.  |  Chen, J., et al. 2024. Am J Cancer Res. 14: 1545-1560. PMID: 38726264
11. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis.  |  Nishimori, H., et al. 1997. Oncogene. 15: 2145-50. PMID: 9393972
12. Cloning and characterization of BAI-associated protein 1: a PDZ domain-containing protein that interacts with BAI1.  |  Shiratsuchi, T., et al. 1998. Biochem Biophys Res Commun. 247: 597-604. PMID: 9647739